- Location
- —
- Roles tracked
- 0
- In pipeline
- 0
- Tracking since
- —
At a glance
You're tracking 0 roles at Immatics. Track a role to start building momentum here.
Company intel
From the job board · LinkedIn data via posting sync- Industry
- Biotechnology Research
- Company size
- 648 people
- Headquarters
- Tuebingen +2 more
- Founded
- 2000
- Type
- Public Company
- Total funding
- $1.0B
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
Discovery of HLA-restricted tumor-associated peptides as cancer targets
Biomarkers
Immunomonitoring
Peptidomics & mass spectrometry
Standardized PBMC collection
Bioinformatics
Immunology
TCR Discovery
Bispecific Development
TCR-based Immunotherapies
Adoptive Cell Therapy
TCR Bispecifics
